Topical MEK Inhibitor

About NFlection Therapeutics

NFlection Therapeutics is a private, clinical-stage biotech company based in Cambridge, USA, founded in 2015. It is pioneering the development of topical MEK inhibitors for rare, RAS-mediated dermatological disorders, with its lead program for cutaneous neurofibromas in NF1 currently in Phase 2. The company's strategy targets high-unmet-need conditions where topical application could offer significant safety and efficacy advantages over systemic therapies. Its pipeline also includes preclinical programs for squamous cell carcinoma prevention in transplant patients and non-surgical treatment of congenital birthmarks.

About NFlection Therapeutics

NFlection Therapeutics is a private, clinical-stage biotech company based in Cambridge, USA, founded in 2015. It is pioneering the development of topical MEK inhibitors for rare, RAS-mediated dermatological disorders, with its lead program for cutaneous neurofibromas in NF1 currently in Phase 2. The company's strategy targets high-unmet-need conditions where topical application could offer significant safety and efficacy advantages over systemic therapies. Its pipeline also includes preclinical programs for squamous cell carcinoma prevention in transplant patients and non-surgical treatment of congenital birthmarks.

About NFlection Therapeutics

NFlection Therapeutics is a private, clinical-stage biotech company based in Cambridge, USA, founded in 2015. It is pioneering the development of topical MEK inhibitors for rare, RAS-mediated dermatological disorders, with its lead program for cutaneous neurofibromas in NF1 currently in Phase 2. The company's strategy targets high-unmet-need conditions where topical application could offer significant safety and efficacy advantages over systemic therapies. Its pipeline also includes preclinical programs for squamous cell carcinoma prevention in transplant patients and non-surgical treatment of congenital birthmarks.

Therapeutic Areas